These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 18257907

  • 1. Both patient characteristics and IVIG product-specific mechanisms may affect eosinophils in immunoglobulin-treated Kawasaki disease.
    Khan S, Doré PC, Sewell WA.
    Pediatr Allergy Immunol; 2008 Mar; 19(2):186-7. PubMed ID: 18257907
    [No Abstract] [Full Text] [Related]

  • 2. Patient characteristics and intravenous immunoglobulin product may affect eosinophils in Kawasaki disease.
    Kuo HC, Wang CL, Wang L, Yu HR, Yang KD.
    Pediatr Allergy Immunol; 2008 Mar; 19(2):184-5. PubMed ID: 18257906
    [No Abstract] [Full Text] [Related]

  • 3. The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease.
    Kuo HC, Yang KD, Liang CD, Bong CN, Yu HR, Wang L, Wang CL.
    Pediatr Allergy Immunol; 2007 Jun; 18(4):354-9. PubMed ID: 17584314
    [Abstract] [Full Text] [Related]

  • 4. Treatment of Kawasaki disease using locally product intravenous immunoglobulin.
    Sangtawesin C, Kirawitaya T, Layangkool T, Nawasiri W, Vimolsarawong N.
    J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S656-60. PubMed ID: 14700163
    [Abstract] [Full Text] [Related]

  • 5. Association of lower eosinophil-related T helper 2 (Th2) cytokines with coronary artery lesions in Kawasaki disease.
    Kuo HC, Wang CL, Liang CD, Yu HR, Huang CF, Wang L, Hwang KP, Yang KD.
    Pediatr Allergy Immunol; 2009 May; 20(3):266-72. PubMed ID: 19438983
    [Abstract] [Full Text] [Related]

  • 6. Hair loss as a sign of Kawasaki disease.
    Nabavizadeh SH, Safari M, Amin R.
    Iran J Allergy Asthma Immunol; 2006 Dec; 5(4):199-200. PubMed ID: 17237574
    [Abstract] [Full Text] [Related]

  • 7. Lessons from Kawasaki disease: all brands of IVIG are not equal.
    Stiehm ER.
    J Pediatr; 2006 Jan; 148(1):6-8. PubMed ID: 16423589
    [No Abstract] [Full Text] [Related]

  • 8. Marked eosinophilia in a patient with history of severe atypical Kawasaki disease.
    O'Byrne ML, Cohen MS.
    Congenit Heart Dis; 2013 Jan; 8(5):E130-3. PubMed ID: 22883471
    [Abstract] [Full Text] [Related]

  • 9. [Immunoglobulin therapy].
    Ogata S, Ishii M.
    Nihon Rinsho; 2014 Sep; 72(9):1617-22. PubMed ID: 25518412
    [Abstract] [Full Text] [Related]

  • 10. Cardiology patient pages. Kawasaki disease.
    Baker AL, Newburger JW.
    Circulation; 2008 Aug 12; 118(7):e110-2. PubMed ID: 18695195
    [No Abstract] [Full Text] [Related]

  • 11. VI nerve palsy after intravenous immunoglobulin in Kawasaki disease.
    Rodríguez-Lozano A, Juárez-Echenique JC, Rivas-Larrauri F, Gámez-González LB, Yamazaki-Nakashimada M.
    Allergol Immunopathol (Madr); 2014 Aug 12; 42(1):82-3. PubMed ID: 23340202
    [No Abstract] [Full Text] [Related]

  • 12. [Immunoregulatory mechanisms of action of intravenous gammaglobulin in Kawasaki syndrome].
    Marcinkiewicz J, Szymanowska Z, Mazurek A.
    Przegl Lek; 1998 Aug 12; 55(11):611-3. PubMed ID: 10216377
    [Abstract] [Full Text] [Related]

  • 13. Role of intravenous immunoglobulin in the treatment of Kawasaki disease.
    Lo MS, Newburger JW.
    Int J Rheum Dis; 2018 Jan 12; 21(1):64-69. PubMed ID: 29205910
    [Abstract] [Full Text] [Related]

  • 14. Acute renal failure and febrile rash--infectious or not? Adult Kawasaki disease (KD).
    El Karoui K, Servais A, Fadel F, Jablonski M, Fakhouri F, Lesavre P, Hummel A.
    Nephrol Dial Transplant; 2007 Mar 12; 22(3):949-51. PubMed ID: 17210597
    [No Abstract] [Full Text] [Related]

  • 15. Resistance to intravenous immunoglobulin (IVIG) in Kawasaki disease: no influence of different IVIG lot utilisation.
    Pagnini I, Marino A, Simonini G, Cimaz R.
    Clin Exp Rheumatol; 2012 Mar 12; 30(1 Suppl 70):S170. PubMed ID: 22410254
    [No Abstract] [Full Text] [Related]

  • 16. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
    Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y.
    Arch Dis Child; 2008 Feb 12; 93(2):142-6. PubMed ID: 17962370
    [Abstract] [Full Text] [Related]

  • 17. Cerebral infarction after high-dose intravenous immunoglobulin therapy for Kawasaki disease.
    Wada Y, Kamei A, Fujii Y, Ishikawa K, Chida S.
    J Pediatr; 2006 Mar 12; 148(3):399-400. PubMed ID: 16615977
    [Abstract] [Full Text] [Related]

  • 18. Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin.
    Tsai MH, Huang YC, Yen MH, Li CC, Chiu CH, Lin PY, Lin TY, Chang LY.
    J Pediatr; 2006 Jan 12; 148(1):38-43. PubMed ID: 16423595
    [Abstract] [Full Text] [Related]

  • 19. Parotitis and kawasaki disease in a child with Noonan syndrome.
    Douvoyiannis M, Belamarich PF, Litman N.
    Pediatr Infect Dis J; 2008 Jan 12; 27(1):89-90. PubMed ID: 18162955
    [No Abstract] [Full Text] [Related]

  • 20. [Aseptic meningitis secondary to intravenous immunoglobulin treatment in Kawasaki disease].
    García Norniella B, Morán Poladura M, Fernández Díaz M, Fernández Fernández E, Suárez Castañón C.
    An Pediatr (Barc); 2011 Jul 12; 75(1):79-80. PubMed ID: 21420919
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.